| | | | | |||||||||||||||||||||
Title of Each Class of
Securities to be Registered |
| |
Amount
Registered(1) |
| |
Proposed
Maximum Offering Price Per Unit(2) |
| |
Proposed
Maximum Aggregate Offering Price(1) |
| |
Amount of
Registration Fee(2) |
| ||||||||||||
Common stock, par value $0.00001
|
| | | | 8,098,592 | | | | | $ | 17.75 | | | | | $ | 143,750,008 | | | | | $ | 15,683.13 | | |
| | | | |
| | | |
PER SHARE
|
| |
TOTAL
|
| ||||||
|
Public Offering Price
|
| | | $ | 17.750 | | | | | $ | 125,000,009 | | |
|
Underwriting Discounts and Commissions(1)
|
| | | $ | 1.065 | | | | | $ | 7,500,001 | | |
|
Proceeds to Aclaris Therapeutics, Inc. before expenses
|
| | | $ | 16.685 | | | | | $ | 117,500,008 | | |
|
Joint Bookrunners
|
| ||||||
|
Jefferies
|
| |
SVB Leerink
|
| |
Piper Sandler
|
|
|
|
| | |
| Table of Contents | | | |||||
| | | | | S-ii | | | |
| | | | | S-iii | | | |
| | | | | S-1 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-8 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-14 | | | |
| | | | | S-22 | | | |
| | | | | S-22 | | | |
| | | | | S-22 | | | |
| | | | | S-23 | | | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 17.75 | | |
|
Net tangible book value per share as of March 31, 2021
|
| | | $ | 2.02 | | | | | | | | |
|
Increase per share attributable to sale of shares of common stock in this offering
|
| | | | 1.74 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | 3.76 | | |
|
Dilution per share to new investors
|
| | | | | | | | | $ | 13.99 | | |
|
Underwriter
|
| |
Number of
Shares |
| |||
Jefferies LLC
|
| | | | 2,605,634 | | |
SVB Leerink LLC
|
| | | | 2,464,789 | | |
Piper Sandler & Co.
|
| | | | 1,971,831 | | |
Total
|
| | | | 7,042,254 | | |
|
| | |
Per Share
|
| |
Total
|
| | | | | | | ||||||||||||||||||
| | |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| | | ||||||||||||||||
Public offering price
|
| | | $ | 17.750 | | | | | $ | 17.750 | | | | | $ | 125,000,009 | | | | | $ | 143,750,008 | | | | | ||||
Underwriting discounts and commissions paid by us
|
| | | $ | 1.065 | | | | | $ | 1.065 | | | | | $ | 7,500,001 | | | | | $ | 8,625,000 | | | | | ||||
Proceeds to us, before expenses
|
| | | $ | 16.685 | | | | | $ | 16.685 | | | | | $ | 117,500,008 | | | | | $ | 135,125,008 | | | | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | |